LKT Labs

Biochemicals for Life Science Research

MLN8237

MLN8237

Product ID M4652
Cas No. 1028486-01-2
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $118.00 In stock
5 mg $219.00 In stock
10 mg $337.00 In stock
Bulk Quote

Quicklinks

Description

MLN8237 inhibits aurora kinase A (AurA) preventing mitotic spindle formation and proper completion of mitosis. MLN8237 exhibits anticancer chemotherapeutic activity and is currently in clinical trials as a potential treatment for multiple myeloma, non-Hodgkin’s lymphoma, and chronic lymphocytic leukemia (CLL). In bladder cancer cells, MLN8237 induces cell cycle arrest, aneuploidy, and apoptosis; in animal models of bladder cancer, this compound inhibits tumor growth. Additionally, MLN8237 inhibits tumor growth of neuroblastomas in vivo as well. In HUVECs, MLN8237 decreases tubule formation and inhibits VEGF secretion, suggesting potential anti-angiogenic activity.

Product Info

Cas No.

1028486-01-2
Purity

≥98%
Formula

C27H20ClFN4O4
Formula Wt.

518.92
IUPAC Name

4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid
Synonym

Alisertib
Solubility

DMSO 27 mg/mL (52.03 mM) Water Insoluble Ethanol Insoluble
Appearance

Pale Yellow Powder

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

M4652 MSDS PDF
Info Sheet

M4652 Info Sheet PDF

References

Romain C, Paul P, Kim KW, et al. Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma. J Pediatr Surg. 2014 Jan;49(1):159-65. PMID: 24439602.

Kelly KR, Shea TC, Goy A, et al. Phase I study of MLN8237-investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs. 2013 Dec 20. [Epub ahead of print]. PMID: 24352795.

Zhou N, Singh K, Mir MC, et al. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin Cancer Res. 2013 Apr 1;19(7):1717-28. PMID: 23403633.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • F4680

    Flutamide

    Non-steroid; AR antagonist.

    ≥98%
  • R5212

    RN-486

    Btk inhibitor.

    ≥98%
  • M177521

    Menaquinone-7

    2-methyl-1,4-naphthoquinone derivative

    98%
  • E6259

    Epoxiconazole

    Triazole; 14-α demethylase inhibitor, potentia...

    ≥95%
  • P2815

    Phenylbutyrate Sodium

    HDAC inhibitor.

    ≥98%
  • Y4802

    YM-201636

    PIKfyve inhibitor.

    ≥98%
  • V3327

    Virginiamycin Mixture

    Macrolide antibiotic

    ≥97%
  • K7602

    KT5823

    PKG inhibitor.

    ≥98%
  • P014442

    Palbociclib

    CDK4/6 inhibitor.

    ≥98%
  • A9715

    AZD-8330

    MEK 1/2 inhibitor.

    ≥98%
  • S0072

    5S rRNA modificator

    Electrophile used in 2’-hydroxyl acylation of...

    ≥98%
  • L0077

    Latrunculin B

    Thiazolidinone macrolide found in the Red Sea s...

    ≥98%
  • T0299

    Tazobactam Sodium

    β-lactamase inhibitor.

    ≥98%
  • A3212

    3′-Azido-3′-deoxythymidine

    Nucleoside (thymidine) analog; DNA chain termin...

    ≥98%
  • C0025

    Cafestol Eicosanate

    Diterpene found in brewed, unfiltered coffee; F...

    ≥98%
  • H9815

    25-Hydroxyvitamin D3

    Vitamin D, calcitriol prodrug; VDR agonist.

    ≥98%
  • E9201

    EX-527

    SIRT1 inhibitor.

    ≥99%
  • D183745

    Destruxin B

    Cyclic depsipeptide is a secondary metabolite i...

    ≥96%
  • M1644

    Meloxicam

    NSAID; COX-2 inhibitor.

    ≥98%
  • R2710

    Recombinant Multi-epitope Chimeric HCV Antigen

    Recombinant Multi-epitope Chimeric HCV antigen....

    ≥95%